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Abstract
Background: Heart failure affects 26 million people globally, and the optimal management of medicines is crucial
for patients, particularly when their care is transferred between hospital and the community. Optimising clinical
outcomes requires well-calibrated cross-organisational processes with staff and patients responding and adapting
to medicines changes. The aim of this study was to assess the feasibility of implementing a complex intervention
(the Medicines at Transitions Intervention; MaTI) co-designed by patients and healthcare staff. The purpose of the
intervention was to optimise medicines management across the gaps between secondary and primary care when
hospitals handover care. The study objectives were to (1) assess feasibility through meeting specified progression
criteria to proceed to the trial, (2) assess if the intervention was acceptable to staff and patients, and (3) determine
whether amendment or refinement would be needed to enhance the MaTI.
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Methods: The feasibility of the MaTI was tested in three healthcare areas in the North of England between July and
October 2017. Feasibility was measured and assessed through four agreed progression to trial criteria: (1) patient
recruitment, (2) patient receipt of a medicines toolkit, (3) transfer of discharge information to community pharmacy,
and (4) offer of a community pharmacy medicines review/discussion or medicines reconciliation. From the
cardiology wards at each of the three NHS Acute Trusts (sites), 10 patients (aged ≥ 18 years) were recruited and
introduced to the ‘My Medicines Toolkit’ (MMT). Patients were asked to identify their usual community pharmacy or
nominate a pharmacy. Discharge information was transferred to the community pharmacy; pharmacists were asked
to reconcile medicines and invited patients for a medicines use review (MUR) or discussion. At 1 month following
discharge, all patients were sent three questionnaire sets: quality-of-life, healthcare utilisation, and a patient
experience survey. In a purposive sample, 20 patients were invited to participate in a semi-structured interview
about their experiences of the MaTI. Staff from hospital and primary care settings involved in patients’ care were
invited to participate in a semi-structured interview. Patient and staff interviews were analysed using Framework
Analysis. Questionnaire completion rates were recorded and data were descriptively analysed.
Results: Thirty-one patients were recruited across three sites. Eighteen staff and 18 patients took part in interviews,
and 19 patients returned questionnaire sets. All four progression to trial criteria were met. We identified barriers to
patient engagement with the intervention in hospital, which were compounded by patients’ focus on returning
home. Some patients described not engaging in discussions with staff about medicines and lacking motivation to
do so because they were preoccupied with returning home. Some patients were unable or unwilling to attend a
community pharmacy in person for a medicines review. Roles and responsibilities for delivering the MaTI were
different in the three sites, and staff reported variations in time spent on MaTI activities. Staff reported some work
pressures and staff absences that limited the time they could spend talking to patients about their medicines.
Clinical teams reported that recording a target dose for heart failure medicines in patient-held documentation was
difficult as they did not always know the ideal or tolerable dose. The majority of patients reported receiving the
patient-held documentation. More than two-thirds reported being offered a MUR by their community pharmacists.
Conclusions: Delivery of the Medicines at Transitions Intervention (MaTI) was feasible at all three sites, and
progression to trial criteria were met. Refinements were found to be necessary to overcome identified barriers and
strengthen delivery of all steps of the intervention. Necessary changes to the MaTI were identified along with
amendments to the implementation plan for the subsequent trial. Future implementation needs to take into
account the complexity of medicines management and adaptation to local context.
Keywords: Heart failure, Cardiology, Care transitions, Complex intervention, Clinical trials, Feasibility studies
Key messages regarding feasibility
 It was uncertain whether the Medicines at
Transitions Intervention could be initiated by a ward
team in an acute hospital setting and continued by a
community pharmacist for heart failure patients
moving across a care transition. It was uncertain
whether patients could be recruited at the required
rate for a cluster randomised controlled trial to be
conducted.
 It was possible to deliver the intervention across the
care transition. The intervention was found to be
feasible and acceptable in three acute trusts and in
the community, although some problems occurred
when patients were discharged outside core hours.
Some information required to deliver some aspects
of the intervention, such as target medication doses,
was not available to staff.
 Changes were recommended to enhance effective
communication between cardiology ward and
hospital pharmacy staff and provide guidance on
discharges occurring at night and weekends, and the
requirement to complete dose titration information
within the MaTI was removed.
Introduction
Heart failure affects 26 million people globally, and poor
outcomes for patients who have been hospitalised as a
result of their heart failure have not improved in line
with advances made in evidence-based treatment [1].
There is also a significant economic burden associated
with being hospitalised and readmitted as a result of the
condition [2]. Heart failure is a condition for which there
is strong evidence for the therapeutic benefit of combi-
nations of medicines at titrated doses [3]. Thus, the opti-
mal management of medicines is crucial to prevent
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readmission to hospital; it can also improve quality of
life and increase the survival rate [4]. However, the man-
agement of medicines is a complex process that involves
patients, their carers, and (potentially) multiple health-
care professionals working in different organisations
[5, 6]. Ensuring optimal clinical outcomes with min-
imal harm requires well-calibrated cross-
organisational processes with staff and patients
responding and adapting to changes such as medicines
changes made by different providers, patient response
to treatment, patient capabilities to manage medicines
routines, and patient co-morbidities [7]. Errors associated
with medicines management can be significant [8, 9], and
the challenges for preventing these are greater when
healthcare providers handover care, for example, on dis-
charge from hospital when medicines changes need to be
communicated with the patient, their carers, and the pa-
tient’s family doctor (General Practitioner; GP) [10]. In
the UK, other healthcare professionals who are part of the
medicines management system are not routinely made
aware of these medicines changes by hospitals; this in-
cludes community pharmacists who dispense patients’
medicines and support their use. Thus, it has been argued
that the implementation of evidence-based medication
therapy could be improved [11, 12].
We have found that there are opportunities to support
patients in playing a more informed and proactive role
in the management of their medicines [13]. and for
healthcare professionals, such as community pharma-
cists, to be more meaningfully integrated into the medi-
cines management system [14]. We have also identified
that despite multiple opportunities for patient safety in-
cidents to occur, staff and patients are able to build re-
silience into this system through temporary or
permanent fixes [7]. Successful interventions to improve
medicines management when care is transferred include
enhanced patient education and better healthcare pro-
fessional communication [15]. However, whole patient
pathway approaches are lacking and there are few inter-
ventions that have been co-designed with their patient
and staff users.
The aim of this study was to assess the feasibility of
implementing a complex intervention (the Medicines at
Transitions Intervention (MaTI)) co-designed by pa-
tients and healthcare staff as part of the programme.
Intervention feasibility was assessed through a set of spe-
cified progression to trial criteria. The purpose of the
intervention was to optimise medicines management
across the gaps between secondary and primary care
when hospitals handover care. In particular, the work re-
ported here is intended to evaluate the acceptability and
deliverability of the intervention by assessing whether
the target patient population could be recruited and
whether data collection tools were fit for purpose.
Following Medical Research Council (MRC) guidance
[16], the study was conducted to enable further refine-
ment of the MaTI and identify potential implementation
problems in advance of a proposed cluster randomised
control trial (cRCT) focussed on the reduction of
readmission and all-cause mortality measured through
routine data sources. An additional aim was to enhance
the implementation of the MaTI in the clinical context
for heart failure medicines management.
Therefore, the objectives of this study were to:
1. Achieve the specified progression criteria to
proceed to the trial;
2. Assess if the intervention components were feasible
to deliver and acceptable to staff and patients and if
the trial data could be collected;
3. Determine whether amendment or refinement of
any intervention components would be needed in
order to enhance deliverability and acceptability.
Methods
We adopted the Consolidated Framework for Implemen-
tation Research (CFIR) [17] as our overall framework for
the development and evaluation of the intervention. A
favourable ethical opinion was provided by a UK
National Health Service Research Ethics Committee (17/
YH/0128). Although this was a non-randomised feasibil-
ity study, where applicable, the principles of the CON-
SORT extension for randomised pilot and feasibility
trials have been adhered to in reporting [18]. Objective 1
was assessed through numbers recruited to the study at
each site and through questionnaires returned by
patients; objective 2 was assessed through site checklists
and qualitative semi-structured interviews with staff and
patients and questionnaires; objective 3 was assessed
through qualitative semi-structured interviews with staff
and patients.
About the intervention
We followed the MRC Framework for intervention
development [16] and conducted a multi-site
Experience-Based Co-Design (EBCD) [19] process with
heart failure patients who had recently been discharged
from hospital, together with their carers and their
healthcare teams [20]. The prototype intervention was
mapped onto behaviour change techniques and refined
based on feedback from a multi-stakeholder panel, in-
cluding commissioners, healthcare professionals, and
patients.
Briefly, the resultant MaTI intervention consisted of
multiple, complementary components designed to opti-
mise medicines management across a common ‘gap’ in
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care when responsibility for patients is transferred be-
tween clinicians in different organisations [21]. It is de-
scribed in Fig. 1 and comprised:
 A patient-held information resource ‘My Medicines
Toolkit’ (MMT) for patients comprising information
about their heart failure medicines, their healthcare
team, and symptoms, plus a checklist for them to
complete detailing events that should have happened
in hospital, at discharge, and after discharge;
 Transfer of discharge information to community
pharmacy to encourage and facilitate medicines
reconciliation [22];
 An invitation to attend a post-discharge medicines
use review (MUR) and/or discussion about their
medicines with the community pharmacist [23].
Intervention checklists were implemented at each site
to track which components of the intervention were de-
livered, and a follow-up checklist was sent to community
pharmacies after patients were discharged to track post-
discharge intervention delivery. The hospital and com-
munity pharmacy checklists were returned to the study
team for analysis.
Progression to trial criteria
In advance, the study’s independent Programme Steering
Committee (comprising academics, clinicians, and a pa-
tient representative) and the funder agreed four criteria
for the feasibility study to progress to trial, with associ-
ated ‘Red’, ‘Amber’, and ‘Green’ (RAG) criteria that were
set to measure and assess performance (Table 1). The
RAG approach was chosen to align with methods estab-
lished for trials using ‘stop’, ‘change’, and ‘go’ progres-
sion criteria [24].
Study setting and patient recruitment
We tested the feasibility of the MaTI in three healthcare
areas in the North of England between July and October
2017. From the cardiology wards of each of the three
NHS Acute Trusts (sites), we recruited 10 patients (aged
≥ 18 years) hospitalised with evidence of at least moder-
ate left ventricular systolic function (left ventricular ejec-
tion fraction < 45%) confirmed within the last 5 years,
and the capacity to provide informed consent. The sam-
ple size was calculated from the first feasibility criterion
of recruiting one patient per week per site over the
course of the study. This target was important to estab-
lish the deliverability of the subsequent clinical trial. In
addition, the qualitative components of the study re-
quired the perspectives of 20 patients; we predicted that,
with dropout, 30 recruited patients would yield that
number of interviews. Patients were assessed for eligibil-
ity and approached on the ward by a research nurse who
explained the study and provided a patient information
leaflet, and if the patient agreed to participate they
gave written informed consent.
Delivering the intervention
Staff were trained to deliver the intervention by a mem-
ber of the research team. As staff roles and responsibil-
ities vary on cardiology wards between sites, we did not
specify which staff should deliver which components of
the intervention: this was decided by sites based on local
staffing. Following recruitment and before their dis-
charge from hospital, patients were introduced to the
personalised MMT by a member of their clinical team.
Staff were also expected to complete a discharge medi-
cines list in the patient's MMT. Patients were asked to
identify their usual community pharmacy or nominate a
pharmacy if they did not usually use one. At discharge,
the discharge advice letter (including the medicines list)
Fig. 1 The Medicines at Transitions Intervention
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was transferred to the community pharmacy, either by
fax or electronically depending on the hospital’s usual
method, along with a written request that the commu-
nity pharmacist will reconcile the patient’s medicines
and invite the patient to a MUR or discussion about
their medicines.
Patient follow-up interviews and surveys
At 1 month following discharge from hospital, all
patients were posted a set of three questionnaires for
self-completion: quality-of-life (EQ 5D 3L) [25],
healthcare utilisation (to capture economic data), and
a patient experience survey (PES). The PES was devel-
oped based on the findings of a multi-site heart fail-
ure medicines management pathway analysis
conducted as part of intervention development work,
and its purpose was to explore patient experiences of
receiving the intervention and with their medicines
[7]. The questions in the survey explored what
patients were told about their medicines at the time
of their discharge from hospital, their use of the My
Medicines Toolkit (MMT), whether they were at least
offered a MUR or medicines discussion by their
community pharmacist after they had left hospital,
and if they actually had a medicines use review. The
EQ 5D 3L and healthcare utilisation questionnaire
were implemented in this feasibility study to deter-
mine if they could be completed and returned by pa-
tients, and their responses are not reported in this
paper. In a purposive sample, 20 patients were invited
to participate in a semi-structured interview about
their experiences of the MaTI and how their
medicines were managed after they left hospital. An
interview schedule was developed exploring their
experiences, and, following gaining written consent,
interviews were undertaken at patients’ homes. A
detailed account of the methods, analysis and results
of the qualitative stage will be reported in a subse-
quent paper. Here, we combine headlines of the
qualitative results as a component of the whole set of
study data.
Staff follow-up interviews
Staff from hospital and primary care settings involved in
patients’ care were invited to participate in a qualitative
face-to-face interview and were provided with a study
information leaflet. Staff approached for interviews
included hospital and community pharmacists, specialist
heart failure nurses, ward nurses, and hospital doctors. If
they agreed to participate, they signed a consent form.
An interview schedule was constructed to explore staff
perceptions of the acceptability and deliverability of the
intervention and their views about the medicines
management pathway. As above, these data will be
reported in full in a subsequent paper.
Data analysis
Patient and staff interviews were audio recorded, tran-
scribed verbatim, and analysed using Framework
Analysis—data were coded and a framework was con-
structed that contained themes describing patients’ med-
icines experiences [26]. Questionnaire completion rates
were recorded, and data were descriptively analysed
using SPSS v.21 [27].
Table 1 Feasibility assessed through progression to trial criteria and their RAG boundaries: if Green, then progression is feasible; if
Amber, then review of the intervention procedure would be necessary; if Red, then the component of the study would not be
deemed deliverable during the cRCT
Criterion RAG
1. Recruitment of a minimum of one patient per week per site (30 participants in
10 weeks across three sites). Assessed at 10 weeks after start of feasibility




2. Patient reported receipt of My Medicines Toolkit (MMT)/Site checklist confirms
patients received MMT
Green:
Evidence that patients received the MMT in all three trusts
Amber:
Evidence that patients received the MMT in two of three trusts
Red:
MMT only delivered in one trust
3. Transfer of discharge advice and medicines letter to community pharmacies in
all three sites—confirmed either by site checklist OR community pharmacy
follow-up
Green:
Evidence that all three trusts able to communicate discharge
advice letter to community pharmacy
Amber: Evidence that two trusts able to transfer this information
Red: Only evidence that one trust is able to transfer information
4. Patients report/community pharmacy report the offer of a community
pharmacy medicines review or medicines discussion OR community pharmacy
reports completion of medicines reconciliation
Green: Evidence that community pharmacies in all three areas able
to offer review or perform medicines reconciliation
Amber: Evidence that community pharmacies in two areas able to
offer these services
Red: Evidence that it has only been possible for community
pharmacies in one area to offer these services
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Results
Overall, 31 patients were recruited across the three sites.
At 1 month following discharge from hospital, three pa-
tients had been readmitted to hospital, one patient had
died and six could not be contacted or did not wish to
continue. Table 2 shows the number of patients re-
cruited from each site and those retained. Table 3 shows
the characteristics of recruited patients. Nine patients
were women, 27 were White British, and four were Brit-
ish Asian, and the mean age was 70 (range 38–93).
Study performance against progression criteria
All progression to trial criteria were met during the
feasibility study, and the more detailed evidence from
patient questionnaires, hospital site checklists, and com-
munity pharmacy questionnaires is detailed in Table 4.
Patient and staff experiences of the intervention
Interviews were conducted with 18 patients: seven from
site 1, three from site 2, and eight from site 3; two of
those interviews were held with a family member who
helped translate. Additionally, interviews were con-
ducted with 18 healthcare professionals: three hospital
heart failure specialist nurses, three consultant cardiolo-
gists, three cardiology ward pharmacists, six community
pharmacists, and three community heart failure nurses.
The in-depth findings of the qualitative data analysis will
be reported in a separate paper. In summary, we identi-
fied barriers to patient engagement with the intervention
in hospital that were compounded by patients’ focus on
returning home. Most patients remembered receiving
the MMT and the member of staff who had introduced
it to them. Some patients described not having engaged
in discussions with staff about medicines and lacking
motivation to do so due to preoccupation with returning
home. Some patients were unable or unwilling to attend
a community pharmacy in person for a MUR and none
reported being offered the option of a telephone MUR.
Roles and responsibilities for delivering the MaTI var-
ied in the three sites, and staff reported variations in
time spent on MaTI activities. They reported some work
pressures and staff absences that limited the time they
could spend talking to patients about their medicines.
Specialist heart failure nurses felt that going through the
toolkit would be more difficult for non-specialist nurses
as they would not have the required specialist know-
ledge. Clinical teams reported that including a target
dose in the MTT for heart failure medicines was not
straightforward as they did not always know what that
was or whether patients could tolerate it. Staff also re-
ported that good internal communication—particularly
between ward and pharmacy staff—was required for suc-
cessful delivery of the MaTI, and their accounts showed
considerable variation across the three sites. Although
there was no pre-existing routine communication with
community pharmacy, hospital staff were able to transfer
information to patients’ community pharmacies. IT sys-
tems such as PharmOutcomes® facilitated this transfer
where available. However, other forms of information
transfer such as paper-based meant that information was
sometimes delayed or did not arrive at the community
pharmacy. If cardiology pharmacy staff did not see pa-
tients prior to discharge, for example, if the discharge
took place in the evening or at weekends, information
was not always transferred. Community pharmacists de-
scribed barriers to inviting patients or patients attending
a review or discussion about their medicines, such as pa-
tients not being well enough to travel to the pharmacy.
However, having discharge information had enabled
community pharmacists to reconcile medicines and con-
duct MURs more meaningfully.
Patient experience survey responses
In total, 19 patients (of 21 available) responded, indicat-
ing that it was possible to collect survey data from pa-
tients following discharge from hospital and that
patients were able to answer most questions on the PES:
four questions required amendments to aid interpret-
ation. Responses to questions related to deliverability
and feasibility of the intervention are summarised in
Table 5. The majority (17) of respondents reported re-
ceiving the MMT, six of whom reported not using it.
More than two-thirds (13) reported being offered a
MUR by their community pharmacist; however, fewer
patients than pharmacists reported that a MUR had
taken place.
Discussion
We found that it was feasible to deliver the MaTI in
three healthcare areas including hospitals and
Table 2 The number of patients recruited and retained at each site
Site 1 Site 2 Site 3 Total
Number of patients recruited 10 11 10 31
Number of patients readmitted 2 0 1 3
Number of patients died 0 1 0 1
Number of patients who could not be contacted or did not wish to continue 1 4 1 6
Number of patients retained through to follow-up 7 6 8 21
Fylan et al. Pilot and Feasibility Studies            (2021) 7:85 Page 6 of 10
community pharmacies and that it was possible to re-
cruit from the target population for the intervention.
Study checklists detailing the intervention steps were
returned from all three sites, which indicated that pa-
tients received the toolkit. Hospitals were able to adapt
systems so that discharge information was transferred to
community pharmacy. Community pharmacies were
able to act on hospital information by reconciling medi-
cines and where appropriate inviting the patient for a
MUR or discussion about their medicines. The majority
of patients who responded to the patient experience sur-
vey reported that they had been offered a review by the
community pharmacist. We demonstrated during the
feasibility study that there was a patient population for
our planned subsequent cRCT. Our criterion of 10 pa-
tients recruited in 10 weeks was met by all sites.
There are clear implications from our study for imple-
menting this type of complex intervention in multiple
healthcare settings. First, implementation needs to take
into account the complexity of medicines management
and adaptation to local context needs to be considered
[28]. Current thinking about complex intervention design
and implementation recommends a fresh focus on the
local environment in planning flexible implementation
and context-specific facilitation, and our study supports
this view [29]. Secondly, and closely linked, training needs
to make clear how to proceed if intervention steps are
missed due to the complexity of care. Assumptions about
Table 3 The characteristics of recruited patients
Site 1 Site 2 Site 3 Totals
Women 2 3 4 9
Male 8 8 6 22
White British 10 9 8 27
British Asian 0 2 2 4
Mean age (median, range), years 63 (61, 38–84) 78 (80, 67–93) 69 (65, 64–81) 70 (65, 38–93)
Total number of patients 10 11 10 31
Table 4 Performance against progression criteria
Criterion Evidence
1 Recruitment All three sites recruited at least ten patients. Two sites did this within 10 weeks and
one site required two additional working days.
2 Patient receipt of MMT Implementation of the MMT was delivered in all three sites. Study checklists were
returned from site 1 (ten), site 2 (eight), and site 3 (ten) and indicated that all patients
received the toolkit.
These data were corroborated by patient reports from 19 returned questionnaires
from site 1 (eight), site 2 (three), and site 3 (eight) indicating that 17/19 patients
received the MMT. In site 1, one patient could not remember receiving it; in site 3,
one patient reported that they did not receive it (however the site checklist records
that they did receive it and the patient answered other questionnaire items
suggesting that they did in fact receive the MMT).
3 Transfer of discharge information All three sites were able to adapt systems so that hospital pharmacists transferred this
information. Checklists from sites 1 and 3 indicate that the information was
transferred for all patients. The eight study checklists returned from site 2 indicate that
information was transferred for four patients. This was because the hospital
pharmacist mistakenly thought that this should not be done if they had not
themselves seen the patient before discharge.
These data were corroborated by community pharmacy data returns: in site 1, eight
reported receiving the patient’s discharge information; 4 reported doing so in site 2;
and eight did so in site 3.
4. Offer of a community pharmacy medicines review or
medicines discussion OR medicines reconciliation
Community pharmacies in all three areas reported acting on hospital information and
reconciling medicines or where appropriate inviting the patient for a Medicines Use
Review (MUR) or discussion about their medicines. Community pharmacy data returns
were received from nine pharmacies in site 1, eight in site 2, and eight in site 3:
In site 1, medicines reconciliation was performed for eight patients; all eight were
offered a MUR/discussion.
In site 2, medicines reconciliation was performed for four patients, two of whom were
offered MURs or medicines discussions.
In site 3, medicines reconciliation was performed for eight patients, seven of whom
were offered a MUR or medicines discussion.
Of the 19 patient survey respondents, 13 reported being offered a review: six from
site 1, one from site 2, and six from site 3.
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the dependency of intervention components also im-
pacted on delivery: some staff thought that missing one
step in the intervention meant that they should not de-
liver subsequent intervention steps. This resulted in inter-
vention stages being left incomplete, for example, if they
did not complete the patient’s fold-out medicines chart in
the MMT, they then did not transfer information to com-
munity pharmacy. Learning about this misconception
allowed us to adapt the intervention training package ac-
cordingly. Additionally, we found in some cases that when
components of the intervention were completed they
were not always recorded on the checklists.
There were also important implications for scale-up to
a trial; for example, we developed information for the
trial implementation guide that encourages active moni-
toring of patient checklists to ensure each intervention
step is taken for every patient. We found that ward staff
do not routinely find out which community pharmacy
the patient uses, so we developed guidance to help staff
to do this and our on-site training includes a session on
helping patients nominate a community pharmacy. We
also introduced a step where the staff member who
transfers discharge information contacts the community
pharmacies by telephone to check that the information
has been received. Finally, we introduced a script for
staff to use that can help guide them through the medi-
cines discussion with patients.
In addition, staff from different teams needed to be
available to deliver parts of the intervention to patients
before discharge including out of hours and at weekends.
However, some staff such as pharmacy staff and special-
ist heart failure nurses were not always available to see
patients in a timely way. Moreover, the focus on return-
ing home for patients meant that they were not always
receptive to receiving medicines information at this
point in their care. Hospitals also had differing systems
for communication with primary healthcare teams. The
subsequent intervention implementation package devel-
oped for the cRCT by our team ensured that staff could
be prepared for these situations and a site coordinator
role was developed for implementation sites to coordin-
ate intervention delivery locally.
We found that the roles and responsibilities allocated
to different healthcare professions on cardiology wards
varied. For example, discussing medicines with patients
may be undertaken by ward staff, hospital-based heart
failure nurses. and pharmacy staff. This confirmed our
intention that we should not specify which staff mem-
bers needed to undertake which intervention steps, and
in our trial intervention sites, the clinical team decided
how to allocate the intervention steps to different staff
types based on local staff mix and practice. Good team
working and communication are essential components
of safe care [30], and we found that effective communi-
cation was necessary between nursing and pharmacy
staff to deliver the MaTI intervention. This included
communication about the timing of discharge so that
the pre-discharge intervention components could be de-
livered, for example, completion of the medicines chart
which was part of the MMT and the medicines that the
patient would be taking home. This informed the design
of our intervention training package and implementation
materials.
The hospitals did not routinely transfer discharge in-
formation to community pharmacy prior to this study,
despite the role that pharmacists can play in identifying
post-discharge medicines problems [31, 32]. We found
that transferring information about heart failure medi-
cines was possible in all three sites, but was not always
achieved in a timely fashion, and community pharmacy
did not always receive this information. Hospitals had
different systems to transfer information, including post
and fax; one site used PharmOutomes®, a web-based sys-
tem that allows messaging between sites. Whilst use of
this type of technology is gradually increasing, our inter-
vention needed to be implementable in sites still using
paper or fax, so in the final intervention we added a step
for the hospital to contact the community pharmacist to
verify that the information had been received.
Whilst heart failure medicines should be titrated to
evidence-based target doses [4], we found that staff did
not always agree with providing a target dose for ACE
inhibitors, angiotensin receptor blockers, and/or beta-
blockers in the patient’s fold-out medicines chart. Some
staff told us that they did not always know what the tar-
get dose was and if they did whether the patient would
tolerate that dose. Consequently, we removed the target
dose from the subsequent intervention; however, the
MMT still indicated that some treatment doses were
intended to be gradually increased once they were back
at home.
The strengths of this study lie in its multi-site delivery,
which included different geographical areas. It also com-
prised a robust assessment of the feasibility of a complex
intervention across a care transition against challenging
progression criteria using the infrastructure that would
Table 5 Responses to the patient experience survey (n = 19)
Question N
Patient given a copy of MMT 17
Patient used MMT:
No 6
Between 1 and 5 times 6
Between 6 and 10 times 5
More than 15 times 1
Patient offered a community pharmacy medicines use review 13
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be in place during a clinical trial. Therefore, we consider
the methods used would be transferable to other feasibil-
ity studies. We also tested different methods of transfer-
ring discharge information to community pharmacy.
There are also limitations to take into account. For
example, we knew prior to the study that there would be
a larger number of heart failure patients who met the
clinical inclusion criteria for the study, but were treated
on non-cardiology wards (for example Care of Older
People wards), and this was the case in each of the feasi-
bility study sites. The National Institute of Health and
Care Excellence (NICE) heart failure guidance stipulates
that patients should be treated by specialist cardiology
teams, and this patient population may have been visited
by heart failure specialist nurses during their in-patient
stays if nurses were available and identified as needing
this specialist care. However, our study was limited to
patients on cardiology wards because it is a ward-level
team-based intervention. Furthermore, we knew it would
be tested during a clinical trial in sites that may not have
heart failure outreach service for patients on non-
cardiology wards.
Conclusions
Delivery of the Medicines at Transitions Intervention
(MaTI) was found to be feasible and acceptable at three
test sites, and progression to trial criteria were met.
Areas for refining hospital implementation were estab-
lishing effective communication between cardiology
ward and pharmacy staff, providing guidance on dis-
charges occurring at night and weekends, and develop-
ing an intervention co-ordination role. In primary care,
community pharmacists reported making use of dis-
charge medicines information to reconcile patients’
medicines but some patients were unable to attend the
pharmacy for a MUR. Refinements were made to
strengthen delivery of all steps of the intervention and to
the implementation plan for the trial.
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